

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	An assignment of equal and undivided share
CONVEYING PARTY DATA	
Name	Execution Date
AstraZeneca AB	08/02/2007
RECEIVING PARTY DATA	
Name:	NPS Pharmaceuticals, Inc.
Street Address:	383 Colorow Drive
City:	Salt Lake City
State/Country:	UTAH
Postal Code:	84108
Name:	AstraZeneca AB
Street Address:	SE-151 85 Sodertalje
City:	Sodertalje
State/Country:	SWEDEN
Postal Code:	SE-151 85
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	US0605246
CORRESPONDENCE DATA	
Fax Number:	(703)205-8050
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	703-205-8000
Email:	odgerm@bskb.com
Correspondent Name:	Birch, Stewart, Kolasch & Birch, LLP
Address Line 1:	P.O. Box 747
Address Line 4:	Falls Church, VIRGINIA 22040-0747
ATTORNEY DOCKET NUMBER:	5999-0530PWO1

CH \$40.00 US0605246

NAME OF SUBMITTER:

Andrew D. Meikle

Total Attachments: 7

source=20070910AZcotoco#page1.tif

source=20070910AZcotoco#page2.tif

source=20070910AZcotoco#page3.tif

source=20070910AZcotoco#page4.tif

source=20070910AZcotoco#page5.tif

source=20070910AZcotoco#page6.tif

source=20070910AZcotoco#page7.tif

ASSIGNMENT

WHEREAS, AstraZeneca AB, a corporation organized and existing under and by virtue of the laws of SWEDEN, having its head office at SE-151 85 Södertälje, SWEDEN (hereinafter "AstraZeneca AB"), has been assigned all of the rights belonging to the inventors employed by AstraZeneca AB, and AstraZeneca AB is now the owner of their entire right, title and interest in and to the following listed Patent Application in the United States and patents that may be granted therefore in any foreign countries by previous assignment(s), as well as any priority rights on which the below listed Patent Application is based:

PCT Appln. No. PCT/US2006/005246, filed February 15, 2006.

WHEREAS, NPS Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the laws of the U.S.A, having an office at 383 Colorow Drive, Salt Lake City, Utah 84108 (hereinafter "NPS Pharmaceuticals Inc."), along with AstraZeneca AB, entered into and agreed to be bound by an Exclusive Research and Collaboration agreement, said agreement being between AstraZeneca AB and NPS Pharmaceuticals Inc., which was signed on and effective as of March 27, 2001, wherein each party agreed to own an equal and undivided share of the total rights to said

patent application and to be joint owners of said patent application;

NOW, THEREFORE, for value received said AstraZeneca AB has assigned and transferred and does hereby assign and transfer unto the said NPS Pharmaceuticals Inc., its successors and assigns, an equal undivided share, right, title and interest in and to the rights held by AstraZeneca AB in said Patent Application(s) and the invention(s) therein contained, to be held and enjoyed by the said NPS Pharmaceuticals, Inc., its successors and assigns the same as it would have been held and enjoyed by AstraZeneca AB, if this assignment and transfer had not been made.

AstraZeneca AB, hereby represents and warrants that there are no rights or interests outstanding inconsistent with the rights and interest granted herein and that AstraZeneca AB will not execute any instrument or grant or transfer any rights or interests inconsistent therewith, and AstraZeneca AB binds itself and its heirs, executors, administrators, employees and legal representatives, as the case may be, to execute and deliver to the said NPS Pharmaceuticals Inc., its successors and assigns, any further documents or instruments and do any and all further acts that may be deemed necessary by the said NPS Pharmaceuticals Inc., its successors and assigns to file applications for improvements and inventions in any country where it may elect to file such applications, and that may be necessary to vest in the said NPS Pharmaceuticals Inc., its successors and assigns, the title herein

conveyed, or intended so to be, and to enable such title to be recorded in the United States and foreign countries where such application or applications may be filed.

AND, AstraZeneca AB further covenants and agrees, in consideration of the premises, that it, its executors and administrators will, at any time upon request, communicate to the said NPS Pharmaceuticals Inc., its successors and assigns, any facts relating to the said invention and improvements and the history thereof, known to it or its successors and assigns, and that it will testify as to the same in any interference or other proceeding when requested to do so by the said NPS Pharmaceuticals Inc., its successors and assigns.

The undersigned hereby grants the law firm of Birch, Stewart, Kolasch & Birch, LLP the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

AstraZeneca AB

Date

AUG 02 2007

By: 

(Signature)

Anna-Lena Rosendahl, Director, IP Services
Printed Name and title:

NPS Pharmaceuticals, Inc.

Date

By: _____

(Signature)

Barton Giddings, Assistant Corporate Secretary
Printed Name and title:

ASSIGNMENT

WHEREAS, AstraZeneca AB, a corporation organized and existing under and by virtue of the laws of SWEDEN, having its head office at SE-151 85 Södertälje, SWEDEN (hereinafter "AstraZeneca AB"), has been assigned all of the rights belonging to the inventors employed by AstraZeneca AB, and AstraZeneca AB is now the owner of their entire right, title and interest in and to the following listed Patent Application in the United States and patents that may be granted therefore in any foreign countries by previous assignment(s), as well as any priority rights on which the below listed Patent Application is based:

PCT Appln. No. PCT/US2006/005246, filed February 15, 2006.

WHEREAS, NPS Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the laws of the U.S.A, having an office at 383 Colorow Drive, Salt Lake City, Utah 84108 (hereinafter "NPS Pharmaceuticals Inc."), along with AstraZeneca AB, entered into and agreed to be bound by an Exclusive Research and Collaboration agreement, said agreement being between AstraZeneca AB and NPS Pharmaceuticals Inc., which was signed on and effective as of March 27, 2001, wherein each party agreed to own an equal and undivided share of the total rights to said

patent application and to be joint owners of said patent application;

NOW, THEREFORE, for value received said AstraZeneca AB has assigned and transferred and does hereby assign and transfer unto the said NPS Pharmaceuticals Inc., its successors and assigns, an equal undivided share, right, title and interest in and to the rights held by AstraZeneca AB in said Patent Application(s) and the invention(s) therein contained, to be held and enjoyed by the said NPS Pharmaceuticals, Inc., its successors and assigns the same as it would have been held and enjoyed by AstraZeneca AB, if this assignment and transfer had not been made.

AstraZeneca AB, hereby represents and warrants that there are no rights or interests outstanding inconsistent with the rights and interest granted herein and that AstraZeneca AB will not execute any instrument or grant or transfer any rights or interests inconsistent therewith, and AstraZeneca AB binds itself and its heirs, executors, administrators, employees and legal representatives, as the case may be, to execute and deliver to the said NPS Pharmaceuticals Inc., its successors and assigns, any further documents or instruments and do any and all further acts that may be deemed necessary by the said NPS Pharmaceuticals Inc., its successors and assigns to file applications for improvements and inventions in any country where it may elect to file such applications, and that may be necessary to vest in the said NPS Pharmaceuticals Inc., its successors and assigns, the title herein

conveyed, or intended so to be, and to enable such title to be recorded in the United States and foreign countries where such application or applications may be filed.

AND, AstraZeneca AB further covenants and agrees, in consideration of the premises, that it, its executors and administrators will, at any time upon request, communicate to the said NPS Pharmaceuticals Inc., its successors and assigns, any facts relating to the said invention and improvements and the history thereof, known to it or its successors and assigns, and that it will testify as to the same in any interference or other proceeding when requested to do so by the said NPS Pharmaceuticals Inc., its successors and assigns.

The undersigned hereby grants the law firm of Birch, Stewart, Kolasch & Birch, LLP the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

AstraZeneca AB

Date

By:

(Signature)

Anna-Lena Rosendahl

Printed Name

Title:

Director, IP Services

NPS Pharmaceuticals, Inc.

Date

By: Barton W Giddings
(Signature)

AUG 02 2007

Barton Giddings
Printed Name

Title: Assistant Corporate Secretary